The Complete Guide to Hong Kong IP Holding × R&D Structures: Patent Box 5%, R&D 300% Deduction — How to Set It Up, How Much You Can Save, and What Substance You Need
One-sentence takeaway: A Hong Kong IP holding and R&D structure genuinely offers tax room, but a shell holding company gets none of the concessions. Qualifying IP income can be taxed at a 5% preferential rate, and the first HK$2 million of Type B R&D expenditure qualifies for a 300% deduction with 200% on the remainder; the conditions are that the patent box must meet the OECD nexus approach and the R&D enhanced deduction requires the activity to take place in Hong Kong, with documentation, functions and personnel substance all lining up.
How Much Tax Can a Hong Kong IP + R&D Structure Save?
Start with the decision table:
| Item | Standard basis | Concession or key point | Core condition |
|---|---|---|---|
| Corporate profits tax | 16.5% | First HK$2M at 8.25% | Two-tier system, Hong Kong–sourced profits |
| Qualifying IP income | 16.5% | 5% | Patent box, nexus, elective |
| Type B R&D expenditure | No enhancement | First HK$2M at 300%, then 200% | R&D in Hong Kong or a designated local research institution |
| Non-resident royalties | Depends | Common non-associated effective rate ~4.95% | Nature of payment, associated relationship, IP history |
| Large multinational groups | Low rates may be topped up | 15% global minimum tax / HKMTT | Group revenue of EUR 750M or more |
A rough estimate looks like this: if a company has HK$3 million of qualifying Type B R&D expenditure, the tax deduction is not HK$3 million but HK$2M × 300% + HK$1M × 200% = HK$8 million. Estimated at a 16.5% rate, the tax benefit of the deduction itself is at most around HK$1.32 million, roughly NT$5.41 million (using a rough HK$1 ≈ NT$4.1). The actual benefit still depends on whether there is enough taxable profit to absorb it.
Hong Kong's underlying advantages are no capital gains tax, no dividend withholding tax and a territorial source basis of taxation; but IP royalties, offshore passive income and related-party transactions carry special rules, so you cannot look at the headline rate alone.
R&D Enhanced Deduction: How Do You Get the 300%?
The IRD's DIPN 55 divides R&D expenditure into Type A and Type B. Type A is generally a 100% deduction; Type B is the more attractive enhanced deduction — 300% on the first HK$2 million and 200% on the excess, with no overall cap. For the official position, see IRD DIPN 55: https://www.ird.gov.hk/eng/pdf/dipn55.pdf
The point is not to label every engineering cost as R&D, but to show it qualifies as an eligible R&D activity: for example, original, planned investigation carried out to resolve scientific or technological uncertainty, or the development of new materials, devices, products, processes, systems or services before commercial use. Routine testing, general data collection, interface tweaks and plain market research usually should not be treated as qualifying R&D.
The most common pitfall is cross-border outsourcing. If the main R&D is done by an overseas group company and the Hong Kong company merely books entries or holds the IP, the Type B enhanced deduction usually will not hold up. Outsourcing to a designated local research institution has a better chance of qualifying; if you outsource to an overseas team, you must at least keep Hong Kong in-house R&D hours, project documents, version records, test records, technological uncertainty and the ownership of results clearly separated.
Hong Kong Patent Box: How Is the 5% Preferential Rate Calculated?
The Hong Kong patent box regime took effect on 5 July 2024 and applies to qualifying IP income for the 2023/24 year of assessment onwards. The IRD's guidance states that qualifying IP includes eligible patents, plant variety rights and copyrighted software; qualifying income can include IP income from licensing, sale and embedding in the price of a product or service, as well as related compensation. See the official page: https://www.ird.gov.hk/eng/tax/bus_patentbox.htm
The key is the nexus / R&D fraction. Simply put, not all IP income is taxed at 5% — only: qualifying IP income profit × R&D fraction. The R&D fraction in turn depends on who does the R&D, where the R&D is done and whether they are an associated party. Doing the R&D yourself in Hong Kong, or having a qualifying non-associated party do it, is usually more favourable; R&D by an offshore associated party, buying in existing IP, or merely holding it passively will dilute the 5% coverage ratio.
The timing also needs updating: as of 2026-07-13, the 5 July 2026 specified date has passed. That is, for certain non-Hong Kong patents filed on or after 5 July 2026, if you want to validly elect the patent box concession, watch whether a corresponding local Hong Kong patent or plant variety right arrangement is already in place.
How to Set Up an IP Holding Structure: Not Just Opening One Company
The common market skeleton is an "IP holding company + intragroup licensing". The IP holding company holds the patents, software copyright or know-how, and then charges royalties to the operating companies that use the IP. If you add a cost-sharing agreement, you must also spell out the R&D costs each participant bears, the rights it obtains, the markets it can use and how risk is allocated.
What actually gets scrutinised is DEMPE: Development, Enhancement, Maintenance, Protection, Exploitation. If the Hong Kong IP company has no engineering decisions, personnel management, R&D budget control, IP maintenance or commercialisation functions, yet takes most of the IP profit, it is easily adjusted on transfer pricing. Royalties must be arm's-length, ideally supported by comparable licences, a valuation model, board records and an annual review.
FSIE must be considered too. Hong Kong's Foreign-sourced Income Exemption regime has, since 1 January 2023, covered interest, dividends, IP income and certain disposal gains, with exceptions such as economic substance, participation exemption or nexus; from 2024 the scope of foreign-sourced disposal gains was further expanded. See the official explanation: https://www.ird.gov.hk/eng/tax/bus_fsie.htm
If the group's annual consolidated revenue reaches EUR 750 million, you must also assess the 15% global minimum tax and the Hong Kong minimum top-up tax. The HKMTT applies to financial years beginning on or after 1 January 2025; see the official explanation: https://www.ird.gov.hk/eng/tax/bus_beps.htm
Hong Kong vs Singapore: Which One?
| Dimension | Hong Kong | Singapore |
|---|---|---|
| IP income concession | Patent box 5% | IDI commonly 5% / 10% |
| Standard corporate rate | 16.5% | 17% |
| R&D deduction | Type B 300% / 200% | Incentives are usually higher, but the details need case-by-case verification |
| Royalty withholding | Commonly ~4.95% in non-associated situations | Generally 10% |
| IP development requirement | Depends on nexus and local registration requirements | Places more weight on local Singapore development and substance |
If you already have a Hong Kong engineering team, Hong Kong customer contracts and cross-border licensing needs, a Hong Kong structure is usually more direct. If you plan to place the core R&D team, commercial decisions and senior management in Singapore, Singapore is worth comparing alongside. If you only want to park overseas R&D results in a low-tax company, neither place should be handled with a shell company alone. For more practical write-ups on Hong Kong outbound expansion, cross-border tax and company structures, see the Chan & Chung insights articles: https://chanchung.com/zh-hant/insights/
Costs, Process and a Substance Checklist
For budgeting purposes only, the basic maintenance cost of a Hong Kong IP holding company may fall in the range of HK$10,000–30,000 per year, about NT$41,000–123,000; once you add accounting, audit, tax filing, transfer pricing documentation, IP valuation, patent agency and legal documents, the actual annual cost can be noticeably higher. For an early-stage company whose royalty flow is only HK$200,000 or HK$500,000, compliance costs may eat up most of the tax saving; you usually need to work out the break-even point first.
A suggested process: first, take stock of IP, R&D activities, costs, rights ownership and income flows; second, judge which expenditures fall into Type A / Type B and which income might enter the patent box; third, design the licensing, CSA, royalties and board decision documents; fourth, prepare the annual filing, R&D records, transfer pricing and IP registration tracking; fifth, review each year whether the nexus fraction and substance have changed.
Substance checklist:
- Is the R&D activity actually carried out in Hong Kong, or outsourced to a designated local research institution?
- Does the R&D project have technological uncertainty, experiment records, failure records and results records?
- Are IP rights ownership, licensing scope, cost sharing and income attribution consistent?
- Do the royalties have an arm's-length basis, rather than being back-calculated after the fact?
- Are the DEMPE functions genuinely performed in the IP holding company or a related entity?
- For patents newly filed after 5 July 2026, do they meet the corresponding local registration requirements?
- Have FSIE, HKMTT and related-party withholding tax all been checked together?
FAQ
Are Hong Kong and Singapore royalty withholding taxes the same?
No. Hong Kong non-associated non-resident royalties commonly carry an effective rate of around 4.95%; Singapore is generally 10%. But associated parties, the IP's historical holder, tax treaties and the nature of the payment all change the outcome.
Is a Hong Kong IP holding company worth it?
It depends on the royalty flow and the scale of R&D expenditure. If you save only HK$30,000 of tax a year but add HK$80,000 of compliance cost, it is not worth it; only with stable licensing income, real R&D and cross-border use is there room to make the numbers work.
Can the 300% R&D deduction be claimed for all software development?
No. Routine feature development, UI tweaks, maintenance and general testing usually do not amount to qualifying R&D. You must be able to explain the technological uncertainty, the R&D method, the Hong Kong execution records and the results.
Does the 5% patent box apply to trademark income?
Usually not. The Hong Kong patent box focuses on eligible patents, plant variety rights and copyrighted software; trademarks, brands and ordinary customer lists should not directly apply the 5%.
Can a shell IP company get the concessions?
The risk is high. The patent box looks at nexus, the R&D deduction looks at Hong Kong R&D activity, transfer pricing looks at DEMPE, and FSIE looks at economic substance; merely holding IP in name usually is not enough to support the concessions.
Conclusion
The point of a Hong Kong IP holding × R&D structure is not to rewrite the tax rate from 16.5% to 5%, but to place R&D, personnel, rights, documentation, licensing and income flows into one explainable set of facts. To evaluate a specific case, start with the Chan & Chung website (https://chanchung.com/zh-hant/) and the services-page contact entry (https://chanchung.com/zh-hant/services); implementation on the ground should be coordinated by a licensed TCSP, accounting/tax and legal professionals according to the actual structure. The patent box, R&D deductions, FSIE, HKMTT, Singapore IDI, transfer pricing and IP holding arrangements mentioned in this article are all market solutions and compliance context, not described as Chan & Chung's own products or official services; regulated trust or company services are provided by Intelligent Services Limited (TCSP licence number TC010349).